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ABSTRACT
Background The metabolic syndrome (MetS) may
contribute to the increased cardiovascular risk in systemic
lupus erythematosus (SLE). We examined the association
between MetS and disease activity, disease phenotype
and corticosteroid exposure over time in patients
with SLE.
Methods Recently diagnosed (<15 months) patients
with SLE from 30 centres across 11 countries were
enrolled into the Systemic Lupus International
Collaborating Clinics (SLICC) Inception Cohort from 2000
onwards. Baseline and annual assessments recorded
clinical, laboratory and therapeutic data. A longitudinal
analysis of factors associated with MetS in the first
2 years of follow-up was performed using random effects
logistic regression.
Results We studied 1150 patients with a mean (SD)
age of 34.9 (13.6) years and disease duration at
enrolment of 24.2 (18.0) weeks. In those with complete
data, MetS prevalence was 38.2% at enrolment, 34.8%
at year 1 and 35.4% at year 2. In a multivariable
random effects model that included data from all visits,
prior MetS status, baseline renal disease, SLICC Damage
Index >1, higher disease activity, increasing age and
Hispanic or Black African race/ethnicity were
independently associated with MetS over the first 2 years
of follow-up in the cohort.
Conclusions MetS is a persistent phenotype in a
significant proportion of patients with SLE. Renal lupus,
active inflammatory disease and damage are SLE-related
factors that drive MetS development while antimalarial
agents appear to be protective from early in the disease
course.
INTRODUCTION
Women with systemic lupus erythematosus (SLE)
have a greater than fivefold increased risk of clinical
coronary heart disease (CHD) events1 and an
increased burden of subclinical atherosclerosis, as
measured by coronary calcium, carotid plaque,
arterial stiffness and endothelial dysfunction.2–5
Although classic Framingham risk factors are more
prevalent in SLE,6 they do not fully explain this
excess CHD risk.7
The metabolic syndrome (MetS) is a clustering of
related CHD risk factors associated with an
increased cardiovascular risk in the general popula-
tion,8 9 and is a useful clinical tool to identify
patients who may warrant more focused CHD risk
assessment.10 MetS is also more prevalent in SLE
than in matched control populations,11 and may
therefore contribute to the pro-atherogenic envir-
onment in SLE. We have previously shown in a
cross-sectional analysis of patients with recently
diagnosed SLE that MetS occurred in 36.4% of
patients. In this study, MetS was associated with
Black African, Korean and Hispanic race/ethnicity,
a more severe lupus phenotype and exposure to
high-dose corticosteroids.12 The impact of
disease-related factors on MetS development over
time is not yet understood and may differ over the
course of the disease. Understanding the interplay
between disease activity, therapeutic exposure and
MetS in SLE would better inform CHD risk stratifi-
cation and help guide treatment regimens in higher
risk patients.
The Systemic Lupus International Collaborating
Clinics (SLICC) group has developed an inception
cohort to facilitate prospective longitudinal studies
of risk factors for the development of atheroscler-
osis in SLE. Using this inception cohort, we aimed
to investigate the factors associated with MetS in
patients with SLE over the first 2 years of follow-up
in the SLICC Inception Cohort.
METHODS
SLICC Inception Cohort and definition of MetS
The methodology used in this study has been
described previously.12 In brief, the SLICC
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Inception Cohort was established between 2000 and 2009 from
30 centres in 11 countries in North America, Europe and Asia.
Patients were enrolled when ≥4 American College of
Rheumatology (ACR) classification criteria for SLE13 were
recognised, and all patients were enrolled within 15 months of
the date of their diagnosis. There were no other specific exclu-
sion criteria. MetS was defined according to the 2009 definition
described in the Joint Interim Statement from the International
Diabetes Federation Task Force on Epidemiology and
Prevention and interested partners.14
SLE disease activity and damage were assessed using the
Systemic Lupus Erythematosus Disease Activity Index
(SLEDAI-2K)15 and the SLICC/ACR Damage Index (SDI),16
respectively. Clinical features and locally performed laboratory
tests (fasting or non-fasting) to assess disease activity, evaluate
CHD risk factors and define MetS were submitted annually to the
coordinating centre at the University of Toronto. Disease pheno-
type data (anti-dsDNA antibody, complement and thrombocyto-
penia data) were also extracted from the SLEDAI-2K.
Statistical analysis
Potential SLE factors implicated in MetS development were
defined a priori. These represented inflammatory disease activity
(SLEDAI-2K), disease phenotype (such as active renal disease,
thrombocytopenia, high anti-dsDNA antibodies) and therapeutic
exposures including several measures of corticosteroid exposure
(including current dose, past doses and length of course, intra-
venous use/dose, peak dose received between visits and total
cumulative dose). Comparison of continuous data was per-
formed using Wilcoxon’s rank sum test or paired t test, and of
categorical data using χ2 test. Variation of MetS over time was
also assessed in 399 patients with complete 2-year data. In our
longitudinal analysis we included all cases in whom a MetS
status could be determined at any time point, using random
effects logistic regression to account for repeated measures
within individuals. Multiple regression analyses, adjusted for
age, gender and race/ethnicity and the varying prevalence of
MetS over time, were performed initially. Variables were gener-
ated to examine the differential effect of recorded exposures
over time (enrolment vs follow-up). Interactions between pre-
dictor variables and between predictor variables and follow-up
were tested for and included in the multivariable model where
relevant. Factors that were significant on initial adjusted analyses
(p<0.2) were subsequently entered into a multivariable random
effects model. The results presented are adjusted OR and 95%
CIs. All statistical analyses were performed using STATAV.10.0.
RESULTS
Patients
Patient characteristics are summarised in table 1. At enrolment,
the mean (SD) disease duration was 24.2 (18.0) weeks, 1036/
1150 (90.1%) patients were women and there was a wide racial/
ethnic variation, reflecting the geographical distribution of par-
ticipating centres: 516/1148 (45.0%) were Caucasian, 182/1148
(15.9%) were Hispanic, 154/1148 (13.4%) were black African
or Afro-Caribbean and 151/1148 (13.2%) were Korean. All
patients satisfied the 1997 modified ACR criteria for SLE13 and
95.5% of the cohort had a positive ANA. Sufficient data were
available to define the presence or absence of MetS in 1150/
1686 patients (68.2%) at enrolment, 823/1211 patients (68.0%)
at year 1 and 686/1021 patients (67.2%) at year 2. Fasting lipid
data were the most frequent missing item. No significant differ-
ences in age, gender, damage/activity indices, renal disease or
medication use at any time point were noted in patients with
missing MetS status. However, significant differences were
noted in race/ethnicity and country of origin in patients with
missing MetS status. For example, at baseline 79/158 (50%)
patients of African ancestry had missing MetS status compared
with 20/171 (11.7%) Korean subjects, 75/257 (29.2%)
Hispanics and 244/516 (37.8%) Caucasian subjects. These dif-
ferences remained stable over follow-up.
Prevalence of MetS over time
Overall, MetS was present in 439/1150 (38.2%) at enrolment,
286/823 (34.8%) at year 1 and 243/686 (35.4%) at year 2. The
prevalence of MetS varied significantly over time according to
race/ethnicity (figure 1). For example, in Caucasians it occurred
in 35.5%, 32.6% and 31.4% at baseline, year 1 and year 2,
respectively, while in patients of African ancestry the prevalence
of MetS prevalence at each visit was 57%, 38.8% and 62% and
in Koreans it was 41.7% 29.2% and 32.8%, respectively. In a
complete case analysis of the 399 patients with a documented
MetS status at all three visits, 186/399 (46.6%) of patients had
MetS on at least one occasion, 88 (22.1%) had MetS at every
visit, 62 (15.6%) developed incident MetS during follow-up
and 213 (53.4%) never developed MetS (figure 2).
Factors associated with MetS over time
Using random effects logistic regression, we tested the strength of
the association between individual predefined disease-related
variables and MetS over the first 2 years of follow-up in the
whole cohort (n=1150 at enrolment). These analyses were
adjusted for age, race/ethnicity, gender and the varying preva-
lence of MetS over time. As can be seen in table 2, higher disease
activity and SDI scores, renal lupus and higher oral doses of corti-
costeroids were all associated with MetS. Although numbers
were small, intravenous corticosteroid use (eg, at enrolment 52
patients treated with intravenous corticosteroids, 28 of whom
received ≥3 ‘pulses’) also showed a trend towards being asso-
ciated with MetS (OR 1.60, 95% CI 0.87 to 2.97). Current anti-
malarial (AM) use was associated with a reduced prevalence of
MetS over the first 2 years of follow-up (OR 0.21, 95% CI 0.14
to 0.34). Having MetS at the previous visit was most strongly
associated with prevalent MetS (OR 18.6, 95% CI 13.7 to 25.4).
The strength of association between several exposures and
MetS varied according to timing of exposure. For example, the
association between immunosuppressant exposure and MetS
was very strong at baseline but less so over the subsequent
2 years (OR 8.04, 95% CI 4.53 to 14.3 vs OR 2.66, 95% CI
1.47 to 4.76). A similar pattern was seen with peak oral cortico-
steroid dose (per mg) (OR 1.07, 95% CI 1.05 to 1.09 vs OR
1.03, 95% CI 1.01 to 1.04). All univariate results are available
in online supplementary tables S1–S3.
In a final multivariable random effects model we found that
prior MetS status, baseline renal disease, any damage (SDI>1),
higher disease activity, increasing age and Hispanic or African
ancestry race/ethnicity remained independently associated with
MetS over the first 2 years of follow-up. AM use was protective
against MetS development (table 3). When we excluded preced-
ing MetS status from the model, baseline immunosuppressant
use (OR 2.10, 95% CI 1.09 to 4.06), higher peak corticosteroid
dose at baseline (OR 1.04, 95% CI 1.03 to 1.06), AM use over
follow-up (OR 0.27, 95% CI 0.14 to 0.54), SDI>1 over
follow-up (OR 5.24, 95% CI 2.53 to 10.9) and active renal
disease over follow-up (OR 3.62, 95% CI 1.45 to 9.03) were
associated with MetS, in addition to increasing age and African
ancestry and Korean race/ethnicity. Hispanic race/ethnicity did
not remain in this exploratory model.
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Regarding race/ethnicity, almost all patients of Korean race/
ethnicity resided in South Korea (165/169; 97.6%), the majority
of Hispanic patients resided in Mexico (192/240; 80%) or the
USA (39/240; 16.3%) and most patients of African ancestry
resided in either the USA (69.2%) or Europe (20.5%). As
shown in figure 1, the overall prevalence of MetS varied over
time within each racial/ethnic group, but was substantially lower
over the follow-up period in Koreans compared with baseline.
Figure 3 describes the significant variation in MetS phenotype
over time in those of African ancestry, Korean and Hispanic
race/ethnicity compared with the whole cohort. Full character-
istics by race/ethnicity are available in online supplementary
table S4.
DISCUSSION
MetS was common in the SLICC Inception Cohort over the
first 2 years after enrolment, ranging between 34.8% and 38.2%
overall. Despite a high proportion of patients having persistent
MetS at each visit, variation remained in the MetS status of
many individuals over time. For example, over the 2-year
Table 1 Characteristics of patients in the SLICC Inception Cohort over first 2 years*
Enrolment Year 1 Year 2
No. of patients 1150 823 686
Age (years) (mean (SD)) 34.9 (13.6) 36.2 (13.7) 37.2 (13.9)
Gender (%)
Women 1036 (90.1) 729 (88.6) 608 (88.6)
Race/ethnicity (%)
Caucasian 516 (44.9%) 399 (48.5) 347 (50.6%)
Indian subcontinent 37 (3.2) 39 (4.7) 21 (3.1)
Black African 79 (6.9) 49 (6.0) 50 (7.3)
Afro-Caribbean 75 (6.5) 61 (7.4) 41 (6.0)
Korean 151 (13.2) 106 (12.9) 67 (9.8)
Hispanic 182 (15.9) 89 (10.8) 83 (12.1)
Other 108 (9.4) 80 (9.7) 77 (11.2)
CHD risk factors (mean (SD))
BP systolic (mm Hg) 118.5 (16.4) 117.5 (16.8) 117.8 (16.3)
BP diastolic (mm Hg) 74.7 (10.7) 73.9 (10.5) 73.5 (10.6)
On AHT medication (%) 328 (28.5) 259 (31.5) 246 (35.9)
Total cholesterol (mmol/L) 4.89 (1.50) 4.59 (1.11) 4.57 (1.12)
Triglyceride (mmol/L) 1.78 (1.21) 1.45 (1.1) 1.39 (0.95)
HDL-cholesterol (mmol/L) 1.39 (0.61) 1.44 (0.49) 1.43 (0.47)
Lipid-lowering medication (%) 168 (14.6) 138 (16.8) 124 (18.1)
Glucose (mmol/L) 5.02 (1.71) 4.78 (1.00) 4.74 (1.05)
Smoker current (%) 169 (14.7) 113 (13.8) 97 (14.2)
Premenopausal (%) 813 (70.6) 558 (67.8) 464 (67.6)
BMI 24.8 (5.9) 25.4 (5.9) 25.2 (6.1)
WC (cm) 82.0 (14.0) 83.3 (14.9) 82.3 (14.5)
SLEDAI (mean (SD)) 5.4 (5.2) 3.7 (41) 3.7 (4.2)
SLICC/ACR-DI≥1 (%) 97/504 (19.3) 215/815 (26.4) 208/679 (30.6)
Disease phenotype (%)
Active renal disease 261 (22.8) 132 (16.2) 93 (13.6)
Anti-dsDNA positive 427/1034 (41.3) 262/766 (34.2) 227/672 (33.8)
Low complement 419/1038 (40.4) 273/766 (35.6) 229/672 (34.1)
Oral CS use (%) 796 (69.2) 581 (70.6) 401 (58.5)
Oral CS dose (median (IQR))
Average CS dose(mg) 20 (10, 34) 10 (7, 15) 8.0 (5, 12.5)
Highest CS dose(mg) 40 (20, 60) 20 (10, 40) 10 (5, 20)
Cumulative CS dose (g) 2.6 (1.0, 5.0) 3.8 (2.5, 6.1) 5.6 (3.7, 8.9)
Pulse IV CS (%) 52/1095 (4.9) 57/819 (7.0) 24/683 (3.5)
Immunosuppressant use (%) 464 (40.4) 337 (41.0) 299 (43.6)
Azathioprine 196 (43.7) 141 (42.0) 126 (42.3)
Methotrexate 104 (17.4) 62 (18.6) 63 (21.1)
Mycophenolate mofetil 98 (16.4) 65 (19.5) 59 (19.6)
IV cyclophosphamide 95 (15.9) 35 (10.4) 29 (9.9)
Cyclosporin 21 (3.5) 16 (4.7) 14 (4.8)
Other 19 (3.2) 17 (4.1) 8 (2.6)
Antimalarial use (%) 759 (66.0) 555 (67.4) 483 (70.4)
*Denominator is the total patient number unless stated otherwise.
ACR, American College of Rheumatology; AHT, antihypertensive; BMI, body mass index; BP, blood pressure; CHD, coronary heart disease; CS, corticosteroid; HDL, high density
lipoprotein; IV, intravenous; SLEDAI, Systemic Lupus Erythematosus Disease Activity index; SLICC, Systemic Lupus Erythematosus International Collaborating Clinics; WC, waist
circumference.
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follow-up period, 15.6% developed incident MetS and overall
46.6% of patients had MetS on at least one occasion. Whether
persistent or transitory MetS in a young patient with SLE is
associated with future cardiovascular events is a key question
currently under investigation within this cohort, and will help
to further validate the use of MetS as a cardiovascular risk pre-
diction tool in SLE.
As in our baseline analysis,12 we also found significant racial/
ethnic variation in MetS prevalence over time. The highest
prevalence was noted in Hispanic patients and those of African
ancestry at each visit. Korean patients had a high baseline preva-
lence (41.7%) which reduced over time (29.2% at year 1 and
32.8% at year 2), while Caucasian patients had a relatively
stable prevalence at each visit. To some degree, this racial/ethnic
variation in MetS prevalence reflects the background prevalence
of MetS in different populations9 17 18 and the reported higher
rates of MetS in geographically diverse SLE cohorts compared
with their local matched controls.19–23 However, the contrasting
MetS and SLE phenotype observed in these racial/ethnic SLE
populations suggests that central obesity may not be the key
driving factor in all patients in all races/ethnicities. For example,
Hispanic patients and those of African ancestry had persistently
high rates of central obesity but Koreans had a high baseline
prevalence of MetS (which declined over time) despite the
lowest prevalence of central obesity. Corticosteroid use was
almost universal in the Korean population, with frequent early
use of intravenous methylprednisolone, but this group had com-
parable oral corticosteroid doses to the rest of the cohort. An
important question prompted by this observation is whether the
high baseline MetS prevalence in the Korean population in part
reflects a more inflammatory MetS phenotype,19 and therefore
high intravenous/oral corticosteroid use gave rapid control of
active disease and improved inflammation-related metabolic
derangements (and hence reduced MetS). In contrast, long-term
steroid use in Hispanics and those of African ancestry, with a
Figure 1 Prevalence of metabolic syndrome over time by race/
ethnicity. FU, follow-up.
Figure 2 Persistence and variability
of metabolic syndrome (MetS) over
time in a complete case analysis
(n=399). FU, follow-up
Table 2 Significant factors associated with MetS over time in
SLICC Inception Cohort in age, race/ethnicity, gender and time
adjusted univariate analyses*
Variable Adjusted OR 95% CI
Age (years) 1.08 1.06 to 1.11
Previous MetS status 18.6 13.7 to 25.4
African ancestry race/ethnicity 8.11 2.69 to 24.4
Hispanic race/ethnicity 5.17 2.28 to 11.7
SLEDAI-2K>10 2.26 1.54 to 3.32
SLEDAI-2K (per unit) 1.11 1.07 to 1.16
SLICC/ACR-DI>1 7.84 4.32 to 14.2
Active renal disease† 7.31 4.47 to 11.9
Current oral CS 3.94 2.38 to 6.55
Average oral CS dose (mg)‡ 1.06 1.05 to 1.08
Highest oral CS dose (mg)‡ 1.04 1.03 to 1.05
Cumulative oral CS dose (g) 1.11 1.07 to 1.16
Current immunosuppressant 2.06 1.42 to 3.00
Current antimalarial 0.21 0.14 to 0.34
*All variables are assessed as present or absent unless otherwise stated.
†Defined as haematuria >5 red blood cells/high power field; pyuria >5 white blood
cells/high power field; new or recent increase of >500 mg 24 h protein; casts
including granular or red blood cells; or consistent renal biopsy; nephrotic syndrome
(proteinuria >3 g/24 h, oedema and increased BP). Other causes excluded.
‡Within preceding 12 months.
CS, corticosteroid; MetS, metabolic syndrome; SLEDAI, Systemic Lupus Erythematosus
Disease Activity Index; SLICC/ACR-DI, Systemic Lupus Erythematosus International
Collaborating Clinics/American College of Rheumatology Damage Index.
Clinical and epidemiological research
Parker B, et al. Ann Rheum Dis 2015;74:1530–1536. doi:10.1136/annrheumdis-2013-203933 1533
propensity to central obesity, may have a detrimental effect on
the evolution and persistence of MetS. It is likely that genetic
factors may underlie some of these differences by influencing
the SLE phenotype and/or by affecting an individual’s sensitivity
to the effects of corticosteroids.
Our longitudinal study found that factors independently asso-
ciated with MetS over the first 2 years of follow-up in patients
with early SLE include ‘fixed’ factors such as African ancestry
and Hispanic race/ethnicity and age, as well as potentially modi-
fiable factors such as renal disease at enrolment, higher
SLEDAI-2K and the presence of damage on the SDI. Preceding
MetS was most strongly associated with prevalent MetS over the
first 2 years of follow-up, and our complete case analysis con-
firmed that a substantial proportion of patients with MetS at
baseline had persistent MetS at each subsequent visit. Data to
assess whether MetS predates the diagnosis of SLE in these
patients were not collected within the SLICC Inception Cohort.
The association with active lupus, lupus nephritis and damage
suggests that the SLE inflammatory process may contribute to
MetS over time in this population. A more ‘inflammatory’ MetS
phenotype not chiefly driven by central obesity was suggested by
previous studies.11 19 Parker et al noted that low C3 complement
was associated with MetS, and other cross-sectional clinical
studies have also noted associations between aspects of the
inflammatory phenotype and MetS in SLE cohorts, such as previ-
ous nephritis and higher SLEDAI scores24 as well as raised
C-reactive protein.25 In addition, data from lupus-prone mouse
models suggest that MetS and insulin resistance may develop
prior to the actual onset of clinically overt disease.26
Inflammation and progression of SLE may therefore have a key
role in driving MetS over time. The lack of association with
steroid use over time in our final model is of interest. We cannot
exclude an important contribution of steroids to MetS in SLE
and, indeed, in our univariate analysis as well as our exploratory
analysis where we excluded MetS status from the model, both
suggest an important contribution of steroids to this phenotype.
Overall, from a therapeutic point of view, our data suggest that
prompt and focused suppression of disease activity, particularly
nephritis, is likely to have a significant effect on future develop-
ment of MetS in patients with SLE, particularly if this can be
achieved with minimal chronic steroid exposure. Early measures
to control and modulate MetS and cardiovascular risk should
therefore be an additional therapeutic goal in SLE, and recent
experience in renal transplantation has demonstrated that
‘steroid-free’ regimes can be developed in situations where
potent and reliable immunosuppression is clearly required. This
approach has also been proposed in lupus nephritis,27 and our
data suggest that such an approach may have the added benefit of
modifying the long-term risk of cardiovascular disease in SLE.
The independent ‘protective’ effect of AMs on MetS develop-
ment over time observed in this study may reflect the numerous
atheroprotective effects of AMs observed in other studies (such
as on lipid profile and insulin resistance28 29) and positive
effects on disease stability and steroid regimes. There still
remains the possibility that their apparent protective effect on
MetS reflects persistent confounding, such as selection bias,
although this is minimised through the prospective study design
and longer follow-up in our cohort.
This is the largest study to date examining MetS in SLE and
has many advantages over previous studies. First, it is the only
Table 3 Final multivariable random effects model of clinical
associations of MetS over time
Variable Adjusted OR 95% CI
MetS at previous visit (y/n) 14.9 10.7 to 20.8
Renal disease at baseline (y/n) 1.53 1.01 to 2.3
Antimalarial over time (y/n) 0.67 0.47 to 0.95
SLICC/ACR-DI>1 over time (y/n) 2.37 1.64 to 3.42
SLEDAI over time (per unit increase) 1.07 1.02 to 1.13
Age (years) 1.04 1.03 to 1.05
Hispanic 2.25 1.28 to 3.96
African ancestry 3.35 1.59 to 7.01
MetS, metabolic syndrome; SLEDAI, Systemic Lupus Erythematosus Disease Activity
Index; SLICC/ACR-DI, Systemic Lupus Erythematosus International Collaborating
Clinics/American College of Rheumatology Damage Index.
Figure 3 Metabolic syndrome (MetS) characteristics by race/ethnicity. BP, blood pressure; FU, follow-up, HDL, high-density lipoprotein;
TG, triglyceride; WC, waist circumference.
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study that has examined the determinants of MetS over time and
the prospective nature of the cohort limits many potential
sources of bias associated with retrospective studies. Second, the
cohort is young and has a range of disease activity that allows
detailed exploration of the impact of inflammation on MetS
development. Also, the most recent definition of MetS has been
used, which recognises that patients without central obesity can
meet the definition. The effects of non-obesity-related factors on
MetS development could therefore be explored, unlike studies
that use definitions of MetS ‘anchored’ by central obesity. The
SLICC cohort is international and recruited from centres in 11
countries, with a range of racial/ethnic groups and socio-
economic backgrounds, and therefore the results can be general-
ised to a wide range of SLE populations. Finally, and perhaps
uniquely, a broad range of detailed data on corticosteroid dosing
were captured which permitted detailed analyses of the effect of
corticosteroids on MetS, a weakness of existing studies.
The analysis does, however, have several limitations. First,
there are missing MetS data in many patients and particularly
those in the highest risk race/ethnicity group (African ancestry),
a potential source of bias. Second, the use of MetS as a CHD
risk prediction tool has yet to be validated in SLE and is the
focus of ongoing work. Finally, there is no control population
against which to compare the prevalence of MetS, which
hinders the interpretation of the results. While population level
data are available for most participating countries, population
cohorts are generally older with a higher proportion of men
than the SLICC cohort, so direct comparisons cannot be made.
However, all controlled studies to date have found that MetS is
more common in SLE than in age-matched controls.11
Our study found that the risk of developing MetS could be
determined early in the SLE disease course. This clustering of
CHD risk factors and the observed racial/ethnic variation in
MetS susceptibility should help inform risk stratification in indi-
vidual patients and improve the personalised management of
early disease. Lupus nephritis in very early disease, persistent
disease activity and the evolution of damage over time all signifi-
cantly influence the development of MetS, which is a persistent
phenotype in a substantial number of patients. From disease
onset, therapeutic regimes should aim to rapidly control active
disease and should include AMs. Corticosteroid doses should be
individually tailored in order to minimise longer term cardiovas-
cular risk, especially in high-risk populations.
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